Results 191 to 200 of about 21,108 (240)

Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark. [PDF]

Kidney Med
Kjær TT, Lindhardt M, Riis AH, Birn H, Ehlers LH.   +4 more
europepmc   +1 more source

A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease. [PDF]

Cost Eff Resour Alloc
Watema-Lord R, Xie F, Sanyal C.
europepmc   +1 more source

Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial. [PDF]

Int J Endocrinol Metab
Kazem-Nadi S, Keshtkari S, Labbani-Motlagh Z, Mousavi V.   +3 more
europepmc   +1 more source

First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial. [PDF]

Diabetes Obes Metab
Chee YJ, Acharyya S, Liew H, Seow CJ, Goh LL, Boehm BO, Dalan R.   +6 more
europepmc   +1 more source

Effect of Dapagliflozin on Indices of Atrial Myopathy in Rheumatic Heart Disease. [PDF]

JACC Asia
Yusuf J, Nagar A, Gautam A, Mehta V, Gupta MD, Bansal A.   +5 more
europepmc   +1 more source

Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial. [PDF]

Clin Kidney J
Mohamed N, Zayed KN, Elhadedy MA, Badawi MH, Mortada WI, Nabieh KA, Sobh MA, Refaie AF.   +7 more
europepmc   +1 more source

Lack of Short-Term Antiproteinuric Response to Dapagliflozin in a Patient With Dent Disease Type 2. [PDF]

Kidney Int Rep
Jouret F.
europepmc   +1 more source

Circadian reprogramming of inflammation and metabolism in chronic kidney disease. [PDF]

Ren Fail
Li XQ, Cheng L, Chen TF, Ma YN, Li XH, Fu TY, Xiao J, Zhao ZZ.   +7 more
europepmc   +1 more source

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells. [PDF]

Biomedicines
Szachniewicz M, Baran M, Gagat M, Hałas-Wiśniewska M.   +3 more
europepmc   +1 more source